Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Companyâs first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

Employees

Sector

Biotechnology & Medical Research

Calendar

03-11 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
11/12/25	11.96 $	+0.38%	9,005
10/12/25	11.92 $	-3.95%	28,058
09/12/25	12.41 $	-17.54%	173,717
08/12/25	15.05 $	+24.48%	393,450
05/12/25	12.09 $	-36.07%	540,509

Delayed Quote Nasdaq, December 11, 2025 at 06:34 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.92USD

Average target price

40.67USD

Spread / Average Target

+241.16%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed Nasdaq Other stock markets 18:34:28 11/12/2025 GMT			5-day change	1st Jan Change
11.96 ^USD	+0.38%		-36.73%	-47.46%

12-05	Top Premarket Decliners	MT
11-11	Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies	CI

Capitalization	10M 8.51M 7.94M 7.45M 13.78M 902M 15M 92.55M 35.96M 426M 37.53M 36.73M 1.55B	P/E ratio 2025 *	-0.59x	P/E ratio 2026 *	-1.73x
Enterprise value	10M 8.51M 7.94M 7.45M 13.78M 902M 15M 92.55M 35.96M 426M 37.53M 36.73M 1.55B	EV / Sales 2025 *	-	EV / Sales 2026 *	-
Free-Float	11.82%	Yield 2025 *	-	Yield 2026 *	-

12-05	Top Premarket Decliners	MT
11-11	Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies	CI
11-06	Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
10-28	Quoin Pharmaceuticals Ltd. Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 Month 'Whole Body' Data Update from Ongoing Study	CI
10-22	Quoin Pharmaceuticals, Ltd. announced that it has received $16.450005 million in funding from a group of investors	CI
10-21	Quoin Pharmaceuticals announces U.S. FDA grants orphan drug designation for QRX003 in Netherton Syndrome	RE
10-13	Top Premarket Decliners	MT
10-10	Quoin Pharmaceuticals, Ltd. announced that it expects to receive $16.450005 million in funding	CI
10-10	Top Midday Gainers	MT
10-10	Quoin Pharmaceuticals Shares Jump After Announcing $104.5 Million Private Placement	MT
08-18	Quoin Pharmaceuticals Ltd. Appoints Sally Lawlor as Chief Financial Officer, Effective August 18, 2025	CI
08-18	Quoin Pharmaceuticals Names Sally Lawlor as Finance Chief	MT
08-07	Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI

15/03/24	Maxim Group Adjusts Quoin Pharmaceuticals Price Target to $4 From $15, Maintains Buy Rating	MT
10/03/23	JMP Securities Lowers Quoin Pharmaceuticals' Price Target to $6 From $15, Maintains Market Outperform Rating	MT
10/03/23	Ladenburg Thalmann Downgrades Quoin Pharmaceuticals to Neutral From Buy	MT
07/09/22	Alliance Global Partners Initiates Coverage on Quoin Pharmaceuticals With Buy Rating, $20 Price Target	MT
23/08/22	Ladenburg Lowers Quoin Pharmaceuticals' Price Target to $12 From $25, Maintains Buy Rating	MT

Quoin Pharmaceuticals, Ltd. Share Price

Equities

QNRX

US74907L4095

Biotechnology & Medical Research

Valuation: Quoin Pharmaceuticals, Ltd.

Chart: Quoin Pharmaceuticals, Ltd.

Latest news: Quoin Pharmaceuticals, Ltd.

Analysts' recommendations: Quoin Pharmaceuticals, Ltd.

Press Releases: Quoin Pharmaceuticals, Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Quoin Pharmaceuticals, Ltd.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

1 day	+0.38%
1 week	-36.73%
Current month	-44.99%
1 month	+3.95%
3 months	+58.48%
6 months	+40.93%
Current year	-47.46%

1 week	10.5	15.45
1 month	9.82	23.5
Current year	5.01	41.8
1 year	5.01	41.8
3 years	5.01	1,184.4
5 years	5.01	70,638.86
10 years	5.01	70,638.86

Manager	Title	Age	Since
Denise Carter COO	Chief Operating Officer	56	27/10/2021
Michael Myers CEO	Chief Executive Officer	63	27/10/2021
Sally Lawlor DFI	Director of Finance/CFO	42	17/08/2025

Director	Title	Age	Since
Michael Myers CHM	Chairman	63	27/10/2021
Denise Carter BRD	Director/Board Member	56	27/10/2021
Dennis Langer BRD	Director/Board Member	73	27/10/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
QUOIN PHARMACEUTICALS, LTD.	+0.38%	-36.73%	-55.60%	-98.10%	10M
LONZA GROUP AG	-2.53%	-4.41%	+0.34%	+13.12%	47.04B
IQVIA HOLDINGS INC.	+0.46%	-0.18%	+11.67%	+5.34%	37.96B
BEONE MEDICINES AG	+0.06%	-2.68%	+74.93%	+57.87%	35.71B
CELLTRION, INC.	+0.54%	+1.85%	+11.96%	+17.47%	27.64B
MEDPACE HOLDINGS, INC.	+1.12%	+4.06%	+66.01%	+168.30%	15.8B
REVOLUTION MEDICINES, INC.	+0.66%	-0.13%	+68.81%	+229.33%	15.06B
ICON PUBLIC LIMITED COMPANY	+0.68%	+0.94%	-11.62%	-4.84%	14.19B
TEMPUS AI, INC.	-2.73%	-4.17%	+69.37%	-	13.36B
IONIS PHARMACEUTICALS, INC.	+1.18%	-2.84%	+109.24%	+107.76%	12.74B
Average	-0.03%	-4.77%	+34.51%	+55.14%	21.95B
Weighted average by Cap.	-0.33%	-1.90%	+35.06%	+52.31%

	2025 *	2026 *
Net sales	-	-
Net income	-15.44M -13.13M -12.26M -11.5M -21.27M -1.39B -23.16M -143M -55.51M -658M -57.93M -56.7M -2.4B	-17.9M -15.23M -14.22M -13.34M -24.67M -1.61B -26.85M -166M -64.37M -763M -67.17M -65.75M -2.78B
Net Debt	-	-